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Abstractsof Original Contributions:YoungInvestigators
AwardsCompetition
The purpose of the Awards is to find and encourage
the YoungInvestigatorsof promiseon whom the future
of cardiology depends. Any physician/scientist who is
currently in a residency or fellowship training program
or who has been in such a program within the past
3 years is eligible to submit an original investigation.
Medical students and PhD candidates are also eligible
for the competition.
The Judging Committee will select a first and sec-
ond place winner and three honorable mentions for
each of the following categories: a) Clinical Investiga-
tions; b) Physiology, Pharmacology and Pathology; and
c) Molecular and Cellular Cardiology. The Awards will
be presented at the 46th Annual Convocation Cere-
~ younglnv~~tig~to~~A~~ ~~~ ~P~~i~io~:
Physiology, Pharmacology,andPathology
Monday,March17,1997,10:30a.m.–Noon
AnaheimConventionCenter,RoomA19
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(406-1I Hypothyr~idi~mDelays Repolarizationby
Post-transcriptional Inhibition of ths Slow
Component of the Delayed Rectifier K+Current
R.F, Bosch, B.A. Wible, G.-R. Li, S. Nattel. Morrtrea/Heart hstifute,
Montreal, Quebec, Canada
Hypothyroidism is associated with QT prolongation, but rarely Torsades de
Pointes arrhythmias. To evaluate the molecular and ionic basis of hypothy-
roid (H) effects, we studied the ionic currents determining action potential
duration by whole-cell patch clamp techniques in control (C) and H guinea
pig (GP) ventricular myoeytes. Changes in gene expression were assessed
by Northern Blot analysis. Results: HGP (thyroidectomy and PTU) had signif-
icantly longer RR (293 * 6 ms, mean + SE) and QTc intewals (300 + 3 ms)
than CGP (199 +4, 242 + 3 ms, respectively, p c 0.0001 for each). Action
potential duration to 90% depolarizationwas also prolonged by H (140 + 6
ms at 4 Hz in HGP va 67 + 5 ms in CGP, p < 0.0001). Dofetilide-resistant IKs
step current densities were decreased by about 65% in cells from HGP attest
VOlta@S positive to +20 mv, eg, at +50 mV k. was 0.79 + 0.18 pWpF (HGP)
vs 2.44 & 0.37 prVpF in controls (p < 0.01). II(stails were reduced by about
60% for activating voltages positive to –20 mV, eg, at +50 mV IIQtail was
0.15 +0.02 in HGP and 0.72&0.12 prVpF in controls (p < 0.001). Dofetilide-
Sensifive11(~CUm?nt densities were unchanged. it(s@VSitiOtI shifted tOmore
positive voltages in hypothyroidism (half-activation voltage 29.5 + 2.2 mV
in HGP vs 21.3 + 2.7 mV in CGP, p c 0.01), while II(,voltage dependence
was unchanged. 11(~~11/lK@MtiO W&3SS@nifiCdly hrger in hypothyroid Cdk
for test pulses from 60 ms to 4.2 s, reflecting a smaller k. Both groups
had similar IKI and Ic. current densities. Ic,voltage-dependent activation
and inactivation properties and kinetics, as well as recove~ from inactiva-
tion, were not altered by hypothyroidism. Northern Blot analysis revealed a
similar expression of minK mRNA in GP ventricle in both groups. Corrc/u-
sion: Hypothyroidism delays depolarization by post-transcriptional inhibition
of iKs.The rarity of Torsades de Pointes despite substantial QT prolongation
in hypothyroid patienta may result from suppression of it(s (and not IK,) in
hypothyroidism, which may therefore be an interesting natural paradigm for
IKsinhibition.
mony on Wednesday, March 19, at 6:00 pm. The Young
Investigator of the Year (first place) for each category
will receive a plaque, a certificate and $2,000. Second
place winners each receive a certificate and a check for
$1,000.The three honorable mentiona each receive a
certificate and a check for $500.
The American College of Cardiology Young Inves-
tigators Awards Competition is supported by grants
from Searle and OtaukaAmerica Pharmaceutical, Inc.
Timothy J. Gardner, MD, I?ACC
Chair
1997 YoungInvestigators Awards Committee
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1406-21lnductionofthe~holestero,metebo,i~PathWay
regulates the farnesylation of RAS in heart csiis. A
new role for RAS in regulating the expression of
muscarinic receptors and G-proteins
A.P.Gadbut, L. Wu, A. Papageorge, J.B. Galper. Brigham and Women’s
Hoapital Harvard Medica/ School, Boston, MA, USA
We previously demonstrated that induction of the cholesterol metabolic path-
way (ICP) by growth of embtyonic chick heart cells in medium supplemented
with LDL depleted serum resulted in a marked increase in responae of the
heart cell to muscarinic stimulation. This effect was associated with a ccadi-
nate increase in levels of museerinic receptors (MR) and G-ai2 which couple
parasympathetic stimulation to a negative chronotropic response (Haigh et
al,, J, Biol. Chem, 263: 15606-15618, 1988). Here we demonstrate that the
ICP increases the level of mRNAs coding for the M2 MR and G-ai2. This
effeef was revereed by the HMG COAraductase inhibitor, mevinolin, and the
famesyltransferase inhibitor, BZA-5b. Since RAS is a famesylated protein,
we studied the effect of ICP on RAS. We demonstrated the novel finding
that in cultured chick heari cells (CHC) much of the RAS ia lecalized in the
cytoplasm in an unfarnesylated, inactive form. ICP resulted in the increased
famesylation and membrane aesoeiation of RAS. To determine whether the
increased membrane association of RAS due to ICP played a role in induction
of the parasympathetic response we determined the effect of ICP and the
expression of RAS mutants on activation of G-a~ promoter driven Iuciferase
activity. ICP increased G-aiz driven Iuciferase activity in CHC suggesting an
effect of ICP on transcriptional control of G-aiz. Cotransfaction of this con-
struct with an activating RAS mutant (Val-12 RAS) also increased Iuciferase
activity while eo-transfection with a dominant negative RAS mutant (Asn-
17 RAS) reversed the effect of ICP on Iuciferase activity. Infeetion of CHC
with an RCAS virus expressing Val-12 RAS resulted in an increase in G-aiz
mRNA and protein. These data demonstrate that RAS was both necessary
and sufficient to induce the effect of ICP on G-au expression. Hence we have
demonstrated a new pathway for the regulation of RAS by cholesterol and a
new function for RAS in the control of cardiac excitability.
